We believe that Destination Maternity Corporation (“Destination Maternity” or the “Company”) has tremendous potential—as evidenced by our collective ownership of almost 9% of the Company’s stock. With our nominees on the Board of Directors of the Company (the “Board”), we believe we can end and reverse the Company’s decline with our turnaround plan and meaningfully improve the value of the Company’s shares.i
Destination Maternity has supposedly been executing on its “turnaround plan” for more than 3 years.ii Despite the Company’s rhetoric about its supposed plan and its focus on “maintain[ing] a stringent profit focused philosophy,”iii the Company’s financial and operating performance has collapsed. In fact, the Company hasn’t had a profitable year since 2014.iv In the last 3 years, Destination Maternity’s:
And the Board hasn’t just presided over these disastrous operating results. It’s also presided over a breakdown in its responsibility to hold management accountable and adhering to corporate governance best practices:
i Based on an expected increase in EBITDA of approximately $40MM and in EPS of approximately $2.00, together with trading multiples of 10x EPS and 6x EBITDA. Comps based on 2018 multiples for NYSE: ANF; NYSE: AEO; NYSE: TPR; NYSE: EXPR; NYSE: GPS; NYSE: KORS; NYSE: LB; NASDAQ: LULU; NASDAQ: PLCE; and NASDAQ: URBN.
ii Destination Maternity Corp., Press Release (Oct. 5, 2017), available at https://www.sec.gov/Archives/edgar/data/896985/000119312517303520/d466668ddefa14a.htm. See also Destination Maternity Corp., Quarterly Report (Form 10-Q) (Dec., 1, 2017), at 20, available at https://www.sec.gov/Archives/edgar/data/896985/000156459017024673/dest-10q_20171028.htm.
iii Destination Maternity Reports Fourth Quarter and Fiscal 2017 Results, Destination Maternity Corp., http://investor.destinationmaternity.com/phoenix.zhtml?c=72323&p=irol-newsEarningsArticle&ID=2343394 (“FY2017 Earnings Release”).
iv Destination Maternity Corp., Annual Report (Form 10-K) (Apr. 19, 2018) at F-4, available at https://www.sec.gov/Archives/edgar/data/896985/000156459018008458/dest-10k_20180203.htm (“FY2017 10-K”); Destination Maternity Corp., Annual Report (Form 10-K) (Apr. 14, 2016) at F-5, available at https://www.sec.gov/Archives/edgar/data/896985/000156459016016192/dest-10k_20160130.htm (“FY2015 10-K”).
v Based on the closing share price of the Company’s stock as of September 30, 2014 ($15.44) and March 23, 2018 ($2.38).
vi Based on the book value of $125.5 million and 13.5 million shares outstanding as of September 30, 2014 and book value of $40.7 million and 13.8 million shares outstanding as of February 3, 2018 (the end of fiscal year 2017). See FY2015 10-K; FY2017 10-K.
vii Based on the Company’s revenue, EBITDA, net income (using the Company’s adjusted net income and GAAP net income) and cash position for the year ended September 30, 2014 and for the year ended February 3, 2018 (fiscal year 2017). FY2015 10-K; FY2017 10-K; see generally Destination Maternity Reports Fourth Quarter and Fiscal 2017 Results, Destination Maternity Corp., http://investor.destinationmaternity.com/phoenix.zhtml?c=72323&p=irol-newsEarningsArticle&ID=2343394.
viii Destination Maternity Corp., Definitive Proxy Statement (DEFC 14A) (Apr. 23, 2018) at 19, available at https://www.sec.gov/Archives/edgar/data/896985/000119312518126986/d508957ddefc14a.htm (“DEST Proxy Statement”); Destination Maternity Corp., Definitive Proxy Statement (DEF 14A) (Sept. 21, 2017) at 16, available at https://www.sec.gov/Archives/edgar/data/896985/000119312517290538/d379315ddef14a.htm; Destination Maternity Corp., Definitive Proxy Statement (DEF 14A) (Apr. 18, 2016) at 16, available at https://www.sec.gov/Archives/edgar/data/896985/000119312516545057/d126489ddef14a.htm; Destination
Maternity Corp., Definitive Proxy Statement (DEF 14A) (Dec. 16, 2014) at 16, available at https://www.sec.gov/Archives/edgar/data/896985/000119312514443802/d827339ddef14a.htm; Destination Maternity Corp., Definitive Proxy Statement (DEF 14A) (Dec. 13, 2013) at 16, available at https://www.sec.gov/Archives/edgar/data/896985/000119312513473148/d624710ddef14a.htm; Destination Maternity Corp., Definitive Proxy Statement (DEF 14A) (Dec. 14, 2012) at 16, available at https://www.sec.gov/Archives/edgar/data/896985/000119312512502775/d450750ddef14a.htm; Destination Maternity Corp., Definitive Proxy Statement (DEF 14A) (Dec. 15, 2011) at 16, available at https://www.sec.gov/Archives/edgar/data/896985/000119312511341125/d271230ddef14a.htm.
ix DEST Proxy Statement at 16, 21.
x See Destination Maternity Corp., Form 8-K (Sept. 8, 2017), available at https://www.sec.gov/Archives/edgar/data/896985/000119312517280702/d454351d8k.htm.
xi See Nathan G. Miller, Letter to Destination Maternity Corp. Board (Apr. 16, 2018), available at https://www.sec.gov/Archives/edgar/data/896985/000091412118000714/dm43100583-exh_c.htm.
xii Based on the closing share price of the Company’s stock as of January 3, 2018 (the day of Ms. Payner-Gregor’s appointment) ($3.05). See Destination Maternity Corp., Form 8-K (Jan. 8, 2018), available at https://www.sec.gov/Archives/edgar/data/896985/000119312518005913/d517214d8k.htm.
xiii Based on the closing share price of the Company’s stock as of May 1, 2018 ($2.88). DEST Proxy Statement at 11, 13.
xiv DEST Proxy Statement at 13.
xv DEST Proxy Statement at 13.
xvi Institutional Shareholder Services, Inc., ISS Proxy Analysis & Benchmark Policy Voting Recommendations (Destination Maternity Corp.) (Oct. 12, 2017) at 1.
xvii Based on an expected 1000 bps increase in EBITDA margin, 500 bps from cost cutting and 500 bps from price increases.
Certain Information Concerning the Participants
This presentation relates to the Investors’ solicitation of proxies in connection with the 2018 annual meeting (the “Annual Meeting”) of stockholders of the Company.
The Investors have filed a definitive proxy statement and an accompanying GOLD proxy card with the SEC to be used to solicit proxies in connection with the Annual Meeting and the election of a slate of director nominees at the Annual Meeting (the “Solicitation”).
Stockholders are advised to read the definitive proxy statement and any other documents related to the Solicitation because they contain important information, including information relating to the participants in the Solicitation. These materials and other materials filed by the Investors with the SEC in connection with the Solicitation are available at no charge on the SEC’s website at http://www.sec.gov. The definitive proxy statement and other relevant documents filed by the Investors with the SEC are also available, without charge, by directing a request to the Investors’ proxy solicitor, Morrow Sodali LLC, 470 West Avenue, Stamford, Connecticut 06902 (Call Collect: (203) 658-9400; Call Toll Free: (800) 662-5200; or Email: NGM@Morrowsodali.com).
Nathan G. Miller, Peter O’Malley, Holly N. Alden, Christopher B. Morgan, Marla A. Ryan, and Anne-Charlotte Windal may be deemed “participants” under SEC rules in the Solicitation. Nathan G. Miller and Peter O’Malley may be deemed to beneficially own the equity securities of the Company described in their statement on Schedule 13D initially filed by Mr. Miller with the SEC on December 27, 2017 (the “Schedule 13D”), as it may be amended from time to time. Except as described in the Schedule 13D, none of the individuals listed above has a direct or indirect interest, by security holdings or otherwise, in the Company or the matters to be acted upon, if any, in connection with the Annual Meeting.